Pliant Therapeutics (PLRX) vs Veru (VERU)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Veru (VERU) has outperformed Pliant Therapeutics (PLRX) over the past year, losing 12.6% versus a loss of 61.6%. Over five years, PLRX leads with a -95.9% price change compared with -97.5% for VERU. Pliant Therapeutics is the larger company by market cap ($36.9 million vs $33.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PLRX | VERU |
|---|---|---|
| Share price | $0.5951 | $1.94 |
| Market cap | $36.89M | $33.08M |
| 1-day change | -4.02% | -8.06% |
| YTD return | -51.22% | -9.35% |
| 1-year return | -61.61% | -12.61% |
| 5-year return | -95.89% | -97.50% |
| EPS (TTM) | $-1.46 | $-0.61 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | — |
| Net income (latest FY) | $-149.34M | $-22.73M |
| 52-week high | $1.67 | $7.33 |
| 52-week low | $0.5719 | $1.93 |
| Distance from 52-week high | -64.37% | -73.53% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +236.08% | +1223.20% |
| Average volume | 408.93K | 193.35K |
| Shares outstanding | 61.99M | 17.05M |
| Employees | 49 | 20 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VERU has outperformed PLRX by 49.0 percentage points over the past year.
About Pliant Therapeutics
PLRX stock →Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees
About Veru
VERU stock →Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally. It provides FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.
Health Care · Biotechnology: Pharmaceutical Preparations · 20 employees
PLRX vs VERU FAQ
Which is bigger, Pliant Therapeutics or Veru?
Pliant Therapeutics (PLRX) is larger, with a market capitalization of $36.89M compared with $33.08M for Veru (VERU).
Which stock has performed better over the past year, PLRX or VERU?
VERU returned -12.61% over the past 12 months, compared with -61.61% for PLRX (price return, excluding dividends). Past performance does not predict future results.
Are Pliant Therapeutics and Veru in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.